Dr Sabine Linn is a professor of translational oncology focusing on breast cancer at Utrecht University, The Netherlands. She gained her medical degree (1991, cum laude) from the State University Leiden, The Netherlands, and her internal medicine board certification (2000) at the University Medical Center Utrecht, The Netherlands. She earned her PhD (1998) from the Free University of Amsterdam, The Netherlands, on the subject of multidrug resistance. She trained further as a scientist at the Netherlands Cancer Institute, Amsterdam, and at Stanford University Medical School, Palo Alto, CA, USA. In 2003, she became a senior staff member in the Division of Medical Oncology, and (since 2005) group leader at the Division of Molecular Pathology at the Netherlands Cancer Institute, Amsterdam, where she and her research group focus on the molecular dissection of breast cancer by differential drug sensitivity. Dr Linn has authored or co-authored 80 peer-reviewed publications.